Mona Kamal1, Sweet Ping Ng2, Salman A Eraj3, Crosby D Rock4, Brian Pham2, Jay A Messer5, Adam S Garden2, William H Morrison2, Jack Phan2, Steven J Frank2, Adel K El-Naggar6, Jason M Johnson7, Lawrence E Ginsberg7, Renata Ferrarotto8, Jan S Lewin9, Katherine A Hutcheson9, Carlos E Cardenas10, Mark E Zafereo9, Stephen Y Lai9, Amy C Hessel9, Randal S Weber9, G Brandon Gunn2, Clifton D Fuller11, Abdallah S R Mohamed12, David I Rosenthal13. 1. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt. 2. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 3. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; School of Medicine, The University of Texas Health Science Center at Houston, McGovern School of Medicine, Houston, TX, USA. 4. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; School of Medicine, Texas Tech University Health Sciences Center, Paul L. Foster School of Medicine, El Paso, TX, USA. 5. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Radiation Oncology, The University of Texas Medical Branch, Galveston, TX, USA. 6. Department of Pathology, Division of Pathology/Lab Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA. 7. Department of Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 8. Department of Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 9. Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 10. Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, USA. 11. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Cancer Biology Program, The University of Texas Graduate School of Biomedical Sciences, Houston, TX, USA. 12. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Cancer Biology Program, The University of Texas Graduate School of Biomedical Sciences, Houston, TX, USA; Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, University of Alexandria, Alexandria, Egypt. Electronic address: ASMohamed@mdanderson.org. 13. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: dirosenthal@mdanderson.org.
Abstract
OBJECTIVES: To investigate the impact of 3-Diminsional (3D) tumor volume (TV) and extent of involvement of primary tumor on treatment outcomes in a large uniform cohort of T3 laryngeal carcinoma patients treated with nonsurgical laryngeal preservation strategies. MATERIALS AND METHODS: The pretreatment contrast-enhanced computed tomography images of 90 patients with T3 laryngeal carcinoma were reviewed. Primary gross tumor volume (GTVp) was delineated to calculate the 3D TV and define the extent of invasion. Cartilage and soft tissue involvement was coded. The extent of invasion was dichotomized into non/limited invasion versus multiple invasion extension (MIE), and was subsequently correlated with survival outcomes. RESULTS: The median TV was 6.6 cm3. Sixty-five patients had non/limited invasion, and 25 had MIE. Median follow-up for surviving patients was 52 months. The 5-year local control and overall survival rates for the whole cohort were 88% and 68%, respectively. There was no correlation between TV and survival outcomes. However, patients with non/limited invasion had better 5-year local control (LC) than those with MIE (95% vs 72%, p = .009) but did not have a significantly higher rate of overall survival (OS) (74% vs 67%, p = .327). In multivariate correlates of LC, MIE maintained statistical significance whereas baseline airway status showed a statistically significance trend with poor LC (p = .0087 and 0.06, respectively). Baseline good performance status was an independent predictor of improved OS (p = .03) in multivariate analysis. CONCLUSION: The extent of primary tumor invasion is an independent prognostic factor of LC of the disease after definitive radiotherapy in T3 larynx cancer.
OBJECTIVES: To investigate the impact of 3-Diminsional (3D) tumor volume (TV) and extent of involvement of primary tumor on treatment outcomes in a large uniform cohort of T3 laryngeal carcinomapatients treated with nonsurgical laryngeal preservation strategies. MATERIALS AND METHODS: The pretreatment contrast-enhanced computed tomography images of 90 patients with T3 laryngeal carcinoma were reviewed. Primary gross tumor volume (GTVp) was delineated to calculate the 3D TV and define the extent of invasion. Cartilage and soft tissue involvement was coded. The extent of invasion was dichotomized into non/limited invasion versus multiple invasion extension (MIE), and was subsequently correlated with survival outcomes. RESULTS: The median TV was 6.6 cm3. Sixty-five patients had non/limited invasion, and 25 had MIE. Median follow-up for surviving patients was 52 months. The 5-year local control and overall survival rates for the whole cohort were 88% and 68%, respectively. There was no correlation between TV and survival outcomes. However, patients with non/limited invasion had better 5-year local control (LC) than those with MIE (95% vs 72%, p = .009) but did not have a significantly higher rate of overall survival (OS) (74% vs 67%, p = .327). In multivariate correlates of LC, MIE maintained statistical significance whereas baseline airway status showed a statistically significance trend with poor LC (p = .0087 and 0.06, respectively). Baseline good performance status was an independent predictor of improved OS (p = .03) in multivariate analysis. CONCLUSION: The extent of primary tumor invasion is an independent prognostic factor of LC of the disease after definitive radiotherapy in T3 larynx cancer.
Authors: Joost L Knegjens; Michael Hauptmann; Frank A Pameijer; Alfons J Balm; Frank J Hoebers; Josien A de Bois; Johannes H Kaanders; Carla M van Herpen; Cornelia G Verhoef; Oda B Wijers; Ruud G Wiggenraad; Jan Buter; Coen R Rasch Journal: Head Neck Date: 2011-03 Impact factor: 3.147
Authors: Frank J P Hoebers; Frank A Pameijer; Josien de Bois; Wilma Heemsbergen; Alfons J M Balm; Jan H Schornagel; Coen R N Rasch Journal: Head Neck Date: 2008-09 Impact factor: 3.147
Authors: Jay C Shiao; Abdallah S R Mohamed; Jay A Messer; Katherine A Hutcheson; Jason M Johnson; Heiko Enderling; Mona Kamal; Benjamin W Warren; Brian Pham; William H Morrison; Mark E Zafereo; Amy C Hessel; Stephen Y Lai; Merril S Kies; Renata Ferrarotto; Adam S Garden; Donald F Schomer; G Brandon Gunn; Jack Phan; Steven J Frank; Beth M Beadle; Randal S Weber; Jan S Lewin; David I Rosenthal; Clifton D Fuller Journal: Head Neck Date: 2017-05-02 Impact factor: 3.147
Authors: Guido B van den Broek; Coen R N Rasch; Frank A Pameijer; Ellen Peter; Michiel W M van den Brekel; I Bing Tan; Jan H Schornagel; Josien A de Bois; Lambert J Zijp; Alfons J M Balm Journal: Cancer Date: 2004-10-15 Impact factor: 6.860
Authors: William M Mendenhall; Christopher G Morris; Robert J Amdur; Russell W Hinerman; Anthony A Mancuso Journal: Head Neck Date: 2003-07 Impact factor: 3.147